Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

Inclusion Criteria for Steps 1, 2, and 3: * HIV-infected * Age greater than or equal to 2 and less than 25 years (Steps 1 and 2 only) * CD4% documented within 120 days of study entry * Participants on antiretroviral therapy (ART) must have been on stable ART regimen for at least 90 days prior to study entry * Able and willing to complete all study immunizations and evaluations * Parent or guardian willing to provide informed consent, if applicable * Participants and/or their partners who are sexually active had to agree to use at least one of the following methods of contraception as long as they are on the study: hormonal birth control drugs (oral, injectable or transdermal); male or female condoms with or without a spermicide; diaphragm/cervical cap with spermicide; intrauterine device (IUD) Inclusion Criteria specific to Step 3: * Participants must have been enrolled in Groups 1 or 3 of previous versions of P1065 * Participants did not have to be less than 25 years of age * Participants must have had serology data from Weeks 0, 4, and 28 from their previous participation in P1065 * Participants must have been within 3.5 years +/- 6 months from the first MCV4 dose received in a previous version of P1065 Exclusion Criteria for Step 1: * Any nonstudy vaccine on study entry day * Any inactive vaccine within 2 weeks prior to study entry * Plans to receive any vaccine 2 weeks after the first injection * Receipt of any live nonstudy vaccine within 4 weeks prior to study entr…